H.R.8662 - Accelerating Access to Critical Therapies for ALS Act116th Congress (2019-2020)
|Sponsor:||Rep. Fortenberry, Jeff [R-NE-1] (Introduced 10/23/2020)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 10/23/2020 Referred to the House Committee on Energy and Commerce. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.8662 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (10/23/2020)
Accelerating Access to Critical Therapies for ALS Act
This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.
The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.
HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.